Home – Cell Symposia: The cancer immunity cycle
Cell Symposia: Infection Biology in the Age of the Microbiome
Related Articles
T’s to the rescue: Expanding the follicular T cell universe in follicular lymphoma
Follicular lymphoma is a neoplastic disease of B cell-rich follicular structures of lymphoid origin. In this issue of Cancer Cell, Abe et al. use multi-omics…
T’s to the rescue: Expanding the follicular T cell universe in follicular lymphoma
Follicular lymphoma is a neoplastic disease of B cell-rich follicular structures of lymphoid origin. In this issue of Cancer Cell, Abe et al. use multi-omics…
Tumor-resident probiotic Clostridium butyricum improves aPD-1 efficacy in colorectal cancer models by inhibiting IL-6-mediated immunosuppression
Xie et al. identify that Clostridium butyricum enhances anti-PD-1 efficacy in colorectal cancer (CRC) and propose the use of this probiotic as an adjuvant for…
Home – Cell Symposia: Towards sustainable agriculture: Genomics, bioengineering, and smart technologies
Cell Symposia: Towards sustainable agriculture: Genomics, bioengineering, and smart technologies
Home – Cell Symposia: Towards sustainable agriculture: Genomics, bioengineering, and smart technologies
Cell Symposia: Towards sustainable agriculture: Genomics, bioengineering, and smart technologies
Comprehensive tumor-immune profiling reveals mediators of paradoxical immune sensitivity in sarcomatoid renal cell carcinoma
Salgia et al. unravel the preferential immune sensitivity of sarcomatoid renal cell carcinoma, revealing heightened tertiary lymphoid structure expression and anti-tumor humoral immune activity. They…
CHI3L3+ immature neutrophils inhibit anti-tumor immunity and impede immune checkpoint blockade therapy in bone metastases
The impact of neutrophil maturation in refractory tumors such as bone metastases remains underexplored. Shi et al. demonstrate that predominant immature neutrophils inhibit anti-tumor immunity…
A pan-KRAS inhibitor and its derived degrader elicit multifaceted anti-tumor efficacy in KRAS-driven cancers
Feng et al. demonstrate the potent antitumor efficacy of MCB-294, a pan-KRAS inhibitor, and MCB-36, a derivative proteolysis-targeting chimera (PROTAC) degrader. MCB-294 engages both active…
Home – Cell Symposia: The cancer immunity cycle
Cell Symposia: Infection Biology in the Age of the Microbiome
Home – Cell Symposia: The cancer immunity cycle
Cell Symposia: Infection Biology in the Age of the Microbiome